Lb Pharmaceuticals (LBRX) Assets (2024 - 2026)

Lb Pharmaceuticals has reported Assets for 3 years, with the latest figure at $393.5 million in Q1 2026.

• For the quarter ending Q1 2026, Assets changed N/A year-over-year to $393.5 million; the trailing twelve-month figure through Mar 2026 stood at $393.5 million (changed N/A YoY), and the FY2025 full-year result was $312.9 million, up 833.18% from the prior year.
• Assets for Q1 2026 stood at $393.5 million, up from $312.9 million in the prior quarter.
• The five-year high for Assets was $393.5 million in Q1 2026, with the low at $33.5 million in Q4 2024.
• Average Assets over 3 years is $265.2 million, with a median of $316.8 million recorded in 2025.
• Peak annual rise in Assets reached 833.18% in 2025, while the deepest fall reached 833.18% in 2025.
• Tracing LBRX's Assets over 3 years: stood at $33.5 million in 2024, then soared by 833.18% to $312.9 million in 2025, then grew by 25.74% to $393.5 million in 2026.
• The last three Assets figures came in at $393.5 million (Q1 2026), $312.9 million (Q4 2025), and $320.7 million (Q3 2025), per Business Quant data.

Peer Comparison